

CLIA #: 31D2026917


PATIENT DEMOGRAPHICS

PATIENT INFORMATION:	PHYSICIAN INFORMATION:	SPECIMEN INFORMATION:
Patient, Test DOB: 1/1/1949 Gender/Age: M/77	Test Physician, MD Test Practice 300 Columbus Circle Suite A, Edison, NJ 08837 (866) 909-7284, Fax:(908) 272-1478	ACCESSION #: TS26-0030X PROCEDURE DATE: 4/19/2026 DATE RECEIVED: 4/20/2026 REPORTED ON: 4/20/2026

CLINICAL INFORMATION

PSA Level = 6.6 ng/mL as provided; Elevated PSA Clinical Stage: T1c assumed, (actual clinical stage will depend on referring physician's evaluation), ICD-10: 97.20

DIAGNOSTIC MAP



DIAGNOSIS SUMMARY

Specimen	Diagnosis	CGS*	GG**	PTI
H	Malignant	7(4+3)	3	100%
G	Malignant	6(3+3)	1	15%

*CGS: Composite Gleason Score, **Grade Group

FINAL DIAGNOSIS

(Based Upon Gross And Microscopic Examination)

Prostate Gland, Ultrasound Guided Needle Biopsies:

- A: PROSTATE, LEFT APEX, BIOPSY:**
- Benign prostatic tissue.
- B: PROSTATE, LEFT LATERAL APEX, BIOPSY:**
- Benign prostatic tissue.
- C: PROSTATE, LEFT MID, BIOPSY:**
- Benign prostatic tissue.
- D: PROSTATE, LEFT LATERAL MID, BIOPSY:**
- Benign prostatic tissue.
- E: PROSTATE, LEFT BASE, BIOPSY:**
- Benign prostatic tissue.

Physician: Test Physician, MD

Medical Director: Reema Jaffar, MD

Electronically signed out by: Test Pathologist, MD

• 300 Columbus Circle, Suite A, Edison, NJ 08837

• Tel: 1-866-909-7284

• Fax: (908) 272-1478

F: PROSTATE, LEFT LATERAL BASE, BIOPSY:

- Benign prostatic tissue.

G: PROSTATE, RIGHT APEX, BIOPSY:

- Prostatic Adenocarcinoma, small focus.
- Gleason Score 6(3+3).
- Involving 15% of total surface area, and 2 of 2 cores.
- Perineural invasion present.

H: PROSTATE, RIGHT LATERAL APEX, BIOPSY:

- Prostatic Adenocarcinoma, small focus.
- Gleason Score 7(4+3); Gleason pattern 4 is 80%.
- Involving 100% of total surface area, and 1 of 1 cores.
- Perineural invasion not seen.

I: PROSTATE, RIGHT MID, BIOPSY:

- Benign prostatic tissue.

J: PROSTATE, RIGHT LATERAL MID, BIOPSY:

- Benign prostatic tissue.


K: PROSTATE, RIGHT BASE, BIOPSY:

- Benign prostatic tissue.


L: PROSTATE, RIGHT LATERAL BASE, BIOPSY:

- Benign prostatic tissue.

IMAGES




H. Adenocarcinoma, Gleason score 7(4+3)



H. PIN2 stain

PARTIN TABLE*

G Score: 7(4+3) PSA: 6.60 ng/mL Clinical Stage: T1c



95% confidence intervals shown in parentheses

KEY OC - Organ Confined Disease SV+ - Seminal Vesicle Involvement
 EPE - Extra-Prostatic Extension LN+ - Lymph Nodal Involvement

COMMENTS

Specific immunostains CK34BE12 and P504S (AMACR) were performed on specimens C and I and the results support the above diagnosis.

The Gleason pattern 4 adenocarcinoma in areas shows large cribriform morphology.

Part H has been reviewed in consultation with Yingtao Zhang, MD who concurs with the above diagnosis.

Results of PTEN and ERG immunohistochemical prostate cancer risk stratification (specimen H):

PTEN: Intact

ERG: Negative

Interpretation: Intermediate risk

PTEN immunohistochemical stain shows intact expression and ERG stain is negative. This immunophenotype is associated with intermediate prognosis and risk of biochemical recurrence in comparison to adenocarcinomas of similar Gleason score.

References: A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst (2016): 108(2):dju346

The new five-tiered prostate Grade Group system, as adopted by WHO, is defined such that each group is associated with a unique prognosis based on PSA biochemical recurrence as an endpoint.

- Grade Group 1: Gleason Score ≤ 6
- Grade Group 2: Gleason Score 7(3+4)
- Grade Group 3: Gleason Score 7(4+3)
- Grade Group 4: Gleason Score 8
- Grade Group 5: Gleason Scores 9-10

In a large (>3500 patients) single institutional study, the 5-year actuarial biochemical recurrence-free survival for biopsy Grade Groups 1-5 were 94.2%, 89.2%, 73.1%, 63.1%, and 54.7%, in patients treated with radical prostatectomy.

A contemporary prostate cancer grading system: a validated alternative to the Gleason Score. Eur Urol. 2016;69(3):428-35. Independent surgical validation of the new prostate cancer Grade-Grouping system. BJU Int. 2016;118(5):763-769.

* James Buchanan Brady Urological Institute, Johns Hopkins Medicine (<http://urology.jhu.edu/prostate/partintables.php>)

GROSS EXAMINATION

SPECIMEN	CORES	LENGTH	INK	SPECIMEN	CORES	LENGTH	INK
A: LEFT APEX	1	1.2 cm		G: RIGHT APEX	2	1.0, 2.2 cm	
B: LEFT LATERAL APEX	1	1.6 cm	Green	H: RIGHT LATERAL APEX	1	1.7 cm	Green
C: LEFT MID	1	1.3 cm		I: RIGHT MID	1	1.7 cm	
D: LEFT LATERAL MID	1	1.7 cm	Green	J: RIGHT LATERAL MID	1	1.4 cm	Green
E: LEFT BASE	1	1.0 cm		K: RIGHT BASE	1	1.1 cm	
F: LEFT LATERAL BASE	1	1.4 cm	Green	L: RIGHT LATERAL BASE	1	1.8 cm	Green

SPECIMENS RECEIVED: 12 containers. Fixative: 10% formalin.

A positive control for each stain has been reviewed and accepted.

Any immunostain(s) used were validated and their performance characteristics determined by LabGenomics. They may not be cleared or approved by the U. S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical purposes. They should not be regarded as investigational or for research. This laboratory has been approved by CLIA 88, designated as a high-complexity laboratory and is qualified to perform these tests.